MSD
  • Home
  • Newsroom
  • Licensing
  • Contact Us
  • About Us
    • Our Values
    • Leadership
    • How We Operate
    • Merck/Schering-Plough Merger
    • Our History
  • Responsibility
    • Ethics And Transparency
    • Access
    • Environment
    • Community
  • Research
    • Discovery And Development
  • Products
    • Vaccins
    • Prescription Products
    • Consumer Products
    • Patients And Caregivers
  • Careers
    • Search/Apply for jobs
    • Explore Careers
    • Life at Merck
    • MSD Careers Worldwide

  • MSD IN EGYPT    

    IMS results for January 2012 indicate that MSD has the fastest growth among the leading 15 pharmaceutical companies. We have achieved a growth of 23% for the month with an evolution index of 126. Our share is at 2.3%, the highest ever, and we are in rank number 5 among the multinational companies. Such outstanding results never come by coincidence and are always a result of doing the right things in the right way.

  • PRODUCT PIPELINE
    view

    Visit our new interactive pipeline, featuring a wide range of product candidates across each phase of development.

    Merck medicine bottles
  • WORKING AT MSD    

    We want to make MSD the pharmaceutical company of choice by recruiting, training and managing the best people. Visit our careers section to learn more about who we are as a company and to discover the many reasons to join Merck.

  
  • Patients & Caregivers
    • Merck Helps™ Programs
    • The Merck Manual — Home Edition
    • The Merck Manual of Health & Aging
    • MerckEngage
    • Adult Vaccination Locator
    • Clinical Trials
  • Healthcare Professionals
    • The Merck Manual
    • MerckMedicus
    • Merck Services
    • Authorized Distributors
    • Clinical Trials
  • Media & Investors
    • News
    • Partnerships
    • Quarterly Financials
    • SEC Filings
    • Annual Reports
    • Presentations & Events
    • Company Statements
    • Media Contacts
    • Investor Contacts
  • Company Statements
    • FOSAMAX®  (alendronate sodium) Statement regarding Osteonecrosis of the Jaw
    • Merck Vaccine Supply Status Update
    •   
    • Podcasts
    • RSS
  • Copyright © 2009-2011 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. All rights reserved.